Rituximab Plus Lenalidomide Versus Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. First Analysis of Survival Endpoints of the Randomized Phase-2 Trial SAKK 35/10
Eva Kimby(Karolinska University Hospital), Emanuele Zucca(Università della Svizzera italiana), Felicitas Hitz(Kantonsspital St. Gallen), Thilo Zander(Luzerner Kantonsspital), Hanne Bersvendsen(University Hospital of North Norway), Peter de Nully Brown(Copenhagen University Hospital), Mario Bergetzi(Kantonsspital Aarau), Hans Hagberg(Uppsala University Hospital), Fatime Krasniqi(University Hospital of Basel), Hanne Hawle(Swiss Group For Clinical Cancer Research), Ulrich Mey(Kantonsspital Graubünden), Michele Ghielmini(Institute of Oncology Research), Simona Berardi(Swiss Group For Clinical Cancer Research), Walter Mingrone(Kantonsschule Olten), Micaela Hernberg(Apple (Israel)), Björn E. Wahlin(Karolinska University Hospital), Urban Novak(University of Bern), Bjørn Østenstad(Oslo University Hospital), Andreas Lohri(Kantonsspital St. Gallen), Andrés J.M. Ferreri(Vita-Salute San Raffaele University), Stefan Dirnhofer(University of Basel), Stéphanie Rondeau(Kantonsspital St. Gallen), Anna Vanazzi(European Institute of Oncology), Ann‐Sofie Johansson(University Hospital of Umeå), Daniel Rauch(Washington University in St. Louis)
Cited by 9
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial
|The Lancet|2009|665
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|568